日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Applying early health technology assessment (e-HTA) to inform investment in novel health technologies in the US

在美国,应用早期卫生技术评估(e-HTA)为新型卫生技术的投资提供信息。

Elsisi, Zizi; Canestaro, William; Steuten, L; Hansen, Ryan

Inflation reduction act impact on pharmaceutical investment: insights from investor interviews

通胀抑制法案对医药投资的影响:来自投资者访谈的见解

Canestaro, William J; Patterson, Julie A; Campbell, Jonathan D

Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment

使用血液生物标志物检测可提高评估认知障碍老年患者的经济效益

Canestaro, William J; Bateman, Randall J; Holtzman, David M; Monane, Mark; Braunstein, Joel B

Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate

雇主提供避孕服务的影响:雇主强制提供避孕服务的成本效益分析

Canestaro, W; Vodicka, E; Downing, D; Trussell, J

Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS)

对 Phibbs 等人的论文《居家与诊所 INR 监测:来自居家 INR 研究 (THINRS) 的成本效用分析》的简要评论

Canestaro, William J

Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)

提高伴随诊断测试价值评估流程的效率和质量:伴随测试评估工具(CAT)

Canestaro, William J; Pritchard, Daryl E; Garrison, Louis P; Dubois, Robert; Veenstra, David L

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review

影响他汀类药物浓度和后续肌病的遗传因素:HuGENet 系统评价

Canestaro, William J; Austin, Melissa A; Thummel, Kenneth E

Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing

他汀类药物基因组学:利用基因检测改善患者疗效和降低医疗成本的机遇

Canestaro, William J; Brooks, David G; Chaplin, Donald; Choudhry, Niteesh K; Lawler, Elizabeth; Martell, Lori; Brennan, Troyen; Wassman, E Robert